Skip to main content

Advertisement

Table 2 Sizing, zeta-potential and antifungal activity of drug, cationic lipid, and polyelectrolyte(s) assemblies

From: Cationic nanoparticles for delivery of amphotericin B: preparation, characterization and activity in vitro

Cationic lipid, drug and polyelectrolyte assemblies D ± δ (nm) ζ ± δ (mV) Viability (%)
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PDDA(1) 171 ± 1 24 ± 2 79 ± 5
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL5000–10000 (1) 92 ± 4 40 ± 1 71 ± 4
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL30000–70000 (1) 138 ± 5 50 ± 3 21 ± 9
DODAB BF (0.6)/AmB (0.005)/CMC (1)/PL70000–150000 (1) 148 ± 5 60 ± 3 13 ± 5
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PDDA (1) 280 ± 2 35 ± 1 27 ± 2
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL5000–10000 (1) 238 ± 1 25 ± 7 37 ± 1
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL30000–70000 (1) 326 ± 5 36 ± 3 23 ± 6
AmB (0.05)/DODAB BF (0.06)/CMC (0.1)/PL70000–150000 (1) 417 ± 3 47 ± 5 11 ± 3
  1. Zeta-average diameter (D) and zeta-potential (ζ) of novel cationic AmB formulations and their effect on C. albicans viability at low and high drug-to-lipid molar proportions. Concentrations are given within parentheses in mg/mL. One should notice that polylysine (PL) with diferent molecular weights may alternatively replace PDDA and be used to control the positive zeta-potential of the outer layer.